long intergenic non-protein coding RNA 917Genealiases: []
Q-omics provides the consensus-scored LINC00917 profile across patient tissues and cancer cell-line models. LINC00917 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC00917 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, LINC00917 RNA expression shows 5,740 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, and STAD as cancer lineages where LINC00917 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00917 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00917 survival associations across molecular data types. LINC00917 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00917 RNA expression–survival associations across cancer types. High LINC00917 expression shows unfavorable associations in COAD, BLCA, ACC and UCS, but favorable associations in LUSC and HNSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC00917 RNA expression.
This table summarizes LINC00917 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00917. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00917 shows lower tumor expression in KIRP and higher tumor expression in COAD, THCA and HNSC. The COAD box plot shows higher LINC00917 RNA expression in tumor versus normal tissue (log2 FC = +0.017, t-test p = .008).
This table shows molecular features associated with LINC00917 in patient tissues and cancer cell lines. In patient samples, LINC00917 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
